Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia

Jiang, Qian; Xu, Lei; Dh, Liu; Ky, Lee; Rp, Gale; Zhang, MJ; Jiang, Bin; Xh, Zhang; Wang, Y; Ss, Chen; Xy, Zhao; Chen, H; Jiang, Hao; Chen, Y-H.; Wang, Han; Yz, Qin; Yr, Liu; Yy, Lai; Lv, Meng; Huang, Xiao‐Jun

doi:10.1038/leu.2013.159

Cited by 10 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Allo-HSCT is no longer the primary treatment option for chronic myelogenous leukemia (CML) patients in the early chronic phase because imatinib exhibited better outcomes than MSD-HSCT in young persons with newly diagnosed CML-CP [ 48 ]. The corresponding percentage of allo-HSCT for CML patients decreased from 22% in 2008 to less than 2% in 2017 in China.…”

Section: Introductionmentioning

confidence: 99%

“… ALL not in remission: allo-HSCT as salvage therapy for refractory or relapsed ALL. Chronic myeloid leukemia (CML) [ 48 , 62 – 64 ]: Allo-HSCT could be considered if patients in CP phase fail to respond to TKIs, depending on their age, consent, and the will of the patient. Patients who are resistant to or intolerant of second-generation TKIs are recommended to receive allo-HSCT.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology

et al. 2018

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used to treat malignant hematological neoplasms and non-malignant hematological disorders. Approximately, 5000 allo-HSCT procedures are performed in China annually. Substantial progress has been made in haploidentical HSCT (HID-HSCT), pre-transplantation risk stratification, and donor selection in allo-HSCT, especially after the establishment of the “Beijing Protocol” HID-HSCT system. Transplant indications for selected subgroups in low-risk leukemia or severe aplastic anemia (SAA) differ from those in the Western world. These unique systems developed by Chinese doctors may inspire the refining of global clinical practice. We reviewed the efficacy of allo-HSCT practice from available Chinese studies on behalf of the HSCT workgroup of the Chinese Society of Hematology, Chinese Medical Association and compared these studies to the consensus or guideline outside China. We summarized the consensus on routine practices of all-HSCT in China and focused on the recommendations of indications, conditioning regimen, and donor selection.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The detailed inclusion criteria, study protocol and medical outcomes have been published previously. 17 Patients who were still alive and at least in CCyR at the end of the study evaluation period in March 2012 were eligible for this HRQOL study, and 222 including 126 and 96 in the imatinib and ISD HSCT groups, respectively, agreed to participate. The response rate was 78.3% in the imatinib group and 66.2% in the ISD HSCT group.…”

Section: Materials and Methods Patientsmentioning

confidence: 99%

Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib

Jiang

et al. 2014

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

To evaluate and compare the health-related quality of life (HRQOL) of patients with newly diagnosed CML in the first chronic phase (CML-CP1) receiving HLA-identical sibling donor (ISD) hematopoietic SCT (HSCT) or imatinib, a cross-sectional study that was part of a prospective cohort study at the Institute of Hematology, Peking University was performed. A total of 222 patients including 126 and 96 in the imatinib and ISD HSCT groups, respectively, were enrolled. HRQOL was measured using the Medical Outcomes Study 36-Item Short-Form Health Survey. The ISD HSCT group functioned significantly better on the role-physical functioning and mental health subscales, as well as the mental component summary (MCS) than the imatinib group. HRQOL was generally comparable to groups in the young population. Multivariate analysis showed that white blood cell countX30 Â 10 9 /L and plts count X450 Â 10 9 /L were the major adverse factors affecting HRQOL in long-term survivors. Imatinib therapy was also an adverse factor affecting the MCS (odds ratio ¼ 1.7, P ¼ 0.032). Thus, long-term CML-CP1 survivors receiving ISD HSCT can attain desirable HRQOL comparable to or better than that of patients receiving imatinib.

show abstract

“…Few studies compared outcome after BC in a comparative way. The general consensus appears that allogeneic HSCT offers a reasonable outcome even in accelerated phase or blast crisis [52][53][54][55][56][57].…”

Section: Graft-versus-host-graft-versus-leukemia Effectsmentioning

confidence: 99%

The role of hematopoietic stem cell transplantation in chronic myeloid leukemia

2015

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (HSCT) is currently recommended as 2nd or 3rd line therapy for patients with chronic myeloid leukemia (CML) in first chronic phase or as salvage for patients with very advanced disease. As a consequence, numbers of HSCT in chronic phase have dropped significantly since the introduction of tyrosine kinase inhibitors (TKI), numbers of transplants in advanced disease to a lesser extent. These current recommendations consider primarily disease risk, defined as failure of TKI therapy; they might need to be adapted. We propose a more balanced appraisal of HSCT for individual patients which should include disease risk, transplant risk, and macroeconomic aspects. HSCT should be integrated into the treatment algorithms from diagnosis and be considered very early at first TKI failure for patients with high disease but low transplant risk. For patients with very advanced disease and high transplant risk in contrast, HSCT might only be recommended in a restricted research setting.

show abstract

Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia

Cited by 10 publications

References 13 publications

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology

Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib

The role of hematopoietic stem cell transplantation in chronic myeloid leukemia

Contact Info

Product

Resources

About